Pironetin reacts covalently with cysteine-316 of α-tubulin to destabilize microtubule

Jianhong Yang, Yuxi Wang, Taijing Wang, Jian Jiang, Catherine Helen Botting, Huanting Liu, Qiang Chen, Jingliang Yang, James Henderson Naismith, Xiaofeng Zhu, Lijuan Chen

Research output: Contribution to journalArticlepeer-review

Abstract

Molecules which alter the normal dynamics of microtubule assembly and disassembly 
include many anticancer drugs in clinical use. So far all such therapeutics target β-tubulin 
and structural biology has explained the basis of their action and permitted design of new 
drugs. However by shifting the profile of β-tubulin isoforms, cancer cells become resistant to 
treatment. Compounds that bind to α-tubulin are less well characterized and unexploited. 
The natural product pironetin is known to bind to α-tubulin and is a potent inhibitor of 
microtubule polymerization. Previous reports had identified that pironetin reacts with lysine-352 
residue however analogues designed on this model had much lower potency which was 
difficult to explain, hindering further development. We report crystallographic and mass 
spectrometric data that reveal that pironetin forms a covalent bond to cysteine-316 in α-tubulin 
via a Michael addition reaction. These data provide a basis for the rational design of α-tubulin targeting chemotherapeutics. 

Original languageEnglish
Article number12103
Number of pages9
JournalNature Communications
Volume7
DOIs
Publication statusPublished - 30 Jun 2016

Fingerprint

Dive into the research topics of 'Pironetin reacts covalently with cysteine-316 of α-tubulin to destabilize microtubule'. Together they form a unique fingerprint.

Cite this